rhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL). Over 10 percent of... Over 10 percent of the general population is estimated to be MBL-deficient.
- Mechanism
- Curator reviewed
MBL deficiency may explain why some but not all individuals who are immunosuppressed develop infectious complications even when they receive prophylactic anti-infectious treatment. Studies have shown a correlation between low MBL levels and susceptibility to serious infections in patients immunosuppressed from chemotherapy, including patients with multiple myeloma undergoing high-dose chemotherapy and hematopoietic stem cell transplantation. rhMBL acts as natural MBL in the body, reducing susceptibility to serious infections.
- Primary indication
- Investigated for use/treatment in immunodeficiency and infectious and parasitic disease (unspecified).Curator reviewed
- Also known as
- Recombinant human mannan-binding protein · Recombinant human mannose-binding lectin · rhMBP
Resolves to
What you can answer from here — as of July 03, 2026
Which drugs share a target with rhMBL, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account